Provided by Tiger Fintech (Singapore) Pte. Ltd.

CytomX Therapeutics

2.38
-0.0100-0.42%
Post-market: 2.420.0400+1.68%19:52 EDT
Volume:973.99K
Turnover:2.35M
Market Cap:374.96M
PE:4.90
High:2.50
Open:2.42
Low:2.38
Close:2.39
Loading ...
Aug 22, 2019

Major Issues Report

Current report, item 5.02
Aug 07, 2019

Major Issues Report

Current report, items 2.02 and 9.01
Aug 07, 2019

Quarterly Report

Quarterly report [Sections 13 or 15(d)]
Jun 21, 2019

Major Issues Report

Current report, item 5.07
Jun 21, 2019

Major Issues Report

[Amend] Current report, item 5.02
Jun 21, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Jun 21, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Jun 21, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Jun 21, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Jun 21, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Jun 21, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Jun 04, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Jun 04, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Jun 04, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
May 31, 2019

Statement Of Changes In Beneficial Ownership

Initial statement of beneficial ownership of securities
May 29, 2019

Major Issues Report

Current report, item 5.02
May 09, 2019

Quarterly Report

Quarterly report [Sections 13 or 15(d)]
May 09, 2019

Major Issues Report

Current report, items 2.02 and 9.01
Feb 08, 2019

Correspondence

[Cover]Correspondence
Mar 14, 2018

[Rev.]Annual Report

CytomX Therapeutics, Inc.